THANK YOU FOR SUBSCRIBING
AMD is one of the leading causes of blindness in adults over 65, and Diabetic Retinopathy is the leading cause of blindness in the world, both of which are the focus of LumiThera
Fremont, CA: Commercial stage private medical device company, LumiThera, raised approximately USD 14 million in a Series C funding round led by WaterStar Capital. Proceeds from the investment round will be used to support further commercialization of its Valeda Light Delivery System for the treatment for dry Age-related Macular Degeneration (AMD), to complete its LIGHTSITE III U.S. clinical trial enrollment, and to pursue regulatory clearance of Valeda in the USA. LumiThera's focus is on creating a multi-wavelength photobiomodulation (PBM) treatment for ocular disorders and diseases.[vendor_logo_first]
"We are very pleased with the investor interest in the company and have now completed the Series C round," stated Clark Tedford, Ph.D., President and CEO. "Our soft launch in Europe in the last year has demonstrated excitement for Valeda as the first approved treatment for dry AMD using Photobiomodulation."
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Atlanta based institutional group WaterStar Capital was the lead investor, with participation from Series B investor, Seattle-based Imagine Ventures. The round was also participated by Keiretsu Capital, Water Star Mercury Fund, Nikon Corporation and Celeste Management, a family office. "LumiThera continues to demonstrate clinical benefits with a novel PBM treatment for debilitating eye diseases," stated Daniel Bertholet, a member of LumiThera's Board of Directors. "We are very pleased with the responses by both patients and doctors in Europe over the last year."
Currently, the company is completing enrollment in two prospective, randomized, double-masked, clinical trials; the LIGHTSITE II study in Europe and LIGHTSITE III study in the U.S., using the Valeda Light Delivery System. LumiThera is also planning additional trials for Diabetic Macular Edema (DME) and AMD patients.
AMD is one of the leading causes of blindness in adults over 65, and Diabetic Retinopathy is the leading cause of blindness in the world, both of which are the focus of LumiThera. The company is a leader in the use of PBM for the treatment of acute and chronic ocular diseases and disorders. LumiThera is currently developing the office-based Valeda Light Delivery System to be used by eye care specialists for medical treatment. The Valeda Light Delivery System has been granted authorization to use the CE Mark by an E.U. Notified Body as required for commercial use in the European Economic Area only.
"We see the expansion of the PBM platform into other ocular areas such as Diabetic Retinopathy and Diabetic Macular Edema (DME) as part of the next phase in the global commercialization of the PBM technology platform for ocular damage and disease," stated Yigang Yang, a LumiThera director and founding partner of WaterStar Capital.
More in News